Download PDF
Drug Res (Stuttg) 2023; 73(03): 170-174
DOI: 10.1055/a-1977-8848
Original Article

MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells’ Capability to Proliferate and Migrate

Farah A. Al-Marzook
1   College of Medical and Health Technologies, Al-Zahraa University for Women, Karbala, Iraq
,
Duha Maithem Hassan
1   College of Medical and Health Technologies, Al-Zahraa University for Women, Karbala, Iraq
,
Maha Waleed Alghazal
2   Al-Rafidain University College, Dentistry department, Baghdad, Iraq
,
Rana Abd Alameer Kadheem
3   College of Pharmacy, National University of Science and Technology, Dhi-Qar, Iraq
,
Abduladheem Turki Jalil
4   Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, Iraq
,
Marwan Mahmood Saleh
5   Department of Biophysics, College of Applied Sciences, University of Anbar, Ramadi, Iraq
6   Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction This paper sought to scrutinize the role of microRNA-32 (miR-32) on the growth and migration as well as on the expression of metastatic genes in PC3 cells of prostate cancer in vitro.

Methods Subsequent transfection of cells with miR-32 mimics, miR-32 inhibitor, negative control (NC), cell proliferation using MTT, and apoptosis by ELISA were performed. Furthermore, qRT-PCR was directed to measure the expression levels of matrix metalloproteinase 2 (MMP2) and vascular endothelial growth factors (VEGF) as metastatic and angiogenesis genes in the progression of PC3.

Results miR-32 was overexpressed in PC3 cells compared to normal cells (P<0.001). Down-regulation of miR-32 obstructs in vitro proliferation and migration while intensifying the apoptosis rate in PC3 cells. Also, we found that miR-32 negatively modulates the expression of VEGF and MMP2 in PC3 cells.

Conclusion These results indicate that the suppression of miR-32 might offer an auxiliary treatment procedure for addressing the invasion, progression, and metastasis in PCa patients by improving cell apoptosis.

Key words

prostate cancer - miR-32 - metastasis - proliferation - migration.


Publication History

Received: 18 October 2022

Accepted: 07 November 2022

Article published online:
10 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Siegel RL, Miller KD, Fuchs HE. et al. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33
    Search in Google Scholar
  • 2 Giri VN, Morgan TM, Morris DS. et al. Genetic testing in prostate cancer management: Considerations informing primary care. CA Cancer J Clin 2022; 72: 360-371
    CrossrefPubMedSearch in Google Scholar
  • 3 Dalton GN, Massillo C, Scalise GD. et al. CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice. Cell Death Dis 2019; 10: 299
    CrossrefPubMedSearch in Google Scholar
  • 4 Ferlay J, Colombet M, Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-1953
    CrossrefPubMedSearch in Google Scholar
  • 5 Arap W, Pasqualini R, Costello JF. Prostate Cancer Progression and the Epigenome. N Engl J Med 2020; 383: 2287-2290
    CrossrefPubMedSearch in Google Scholar
  • 6 Pan J, Xue W, Sha J. et al. Incidental prostate cancer at the time of cystectomy: the incidence and clinicopathological features in Chinese patients. PLoS One 2014; 9: e94490
    CrossrefPubMedSearch in Google Scholar
  • 7 Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. Adv Exp Med Biol 2018; 1095: 1-14
    CrossrefPubMedSearch in Google Scholar
  • 8 Chen L, Sun Y, Tang M. et al. High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling. Cell Death Discov 2022; 8: 128
    CrossrefPubMedSearch in Google Scholar
  • 9 Pomerantz MM, Qiu X, Zhu Y. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet 2020; 52: 790-799
    CrossrefPubMedSearch in Google Scholar
  • 10 Sheervalilou R, Ansarin K, Fekri AS. et al. An update on sputum Micro RNA s in lung cancer diagnosis. Diagn Cytopathol 2016; 44: 442-449
    CrossrefPubMedSearch in Google Scholar
  • 11 Mohammadian F, Pilehvar-Soltanahmadi Y, Alipour S. et al. Chrysin alters microRNAs expression levels in gastric cancer cells: possible molecular mechanism. Drug Res 2017; 67: 509-514
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Bazavar M, Fazli J, Valizadeh A. et al. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. Pathol Res Pract 2020; 216: 153176
    CrossrefPubMedSearch in Google Scholar
  • 13 Sheervalilou R, Shahraki O, Hasanifard L. et al. Electrochemical nano-biosensors as novel approach for the detection of lung cancer-related MicroRNAs. Curr Mol Med 2020; 20: 13-35
    CrossrefPubMedSearch in Google Scholar
  • 14 Zhang B, Pan X, Cobb GP. et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12
    CrossrefPubMedSearch in Google Scholar
  • 15 Targhazeh N, Yousefi B, Asghari S. et al. MiR-622 acts as a tumor suppressor to induce cell apoptosis and inhibit metastasis in human prostate cancer. Andrologia 2021; 53: e14174
    CrossrefPubMedSearch in Google Scholar
  • 16 Magee RG, Telonis AG, Loher P. et al. Profiles of miRNA Isoforms and tRNA Fragments in Prostate Cancer. Sci Rep 2018; 8: 5314
    CrossrefPubMedSearch in Google Scholar
  • 17 Strand SH, Schmidt L, Weiss S. et al. Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Sci Rep 2020; 10: 10704
    CrossrefPubMedSearch in Google Scholar
  • 18 Zhu Z, Luo L, Xiang Q. et al. MiRNA-671-5p Promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis. Cell Death Dis 2020; 11: 949
    CrossrefPubMedSearch in Google Scholar
  • 19 Zhao Z, Zhao S, Luo L. et al. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition. Br J Cancer 2021; 124: 982-994
    CrossrefPubMedSearch in Google Scholar
  • 20 Peng Y, Qin Y, Zhang X. et al. MiRNA-20b/SUFU/Wnt axis accelerates gastric cancer cell proliferation, migration and EMT. Heliyon 2021; 7: e06695
    CrossrefPubMedSearch in Google Scholar
  • 21 Fu X, Liu M, Qu S. et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res 2018; 37: 52
    CrossrefPubMedSearch in Google Scholar
  • 22 Zeng ZL, Zhu Q, Zhao Z. et al. Magic and mystery of microRNA-32. J Cell Mol Med 2021; 25: 8588-8601
    CrossrefPubMedSearch in Google Scholar
  • 23 Zhang L, Li X, Chao Y. et al. KLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer. Cell Commun Signal 2018; 16: 53
    CrossrefPubMedSearch in Google Scholar
  • 24 Liang H, Tang Y, Zhang H. et al. MiR-32-5p Regulates Radiosensitization, Migration And Invasion Of Colorectal Cancer Cells By Targeting TOB1 Gene. Onco Targets Ther 2019; 12: 9651-9661
    CrossrefPubMedSearch in Google Scholar
  • 25 Xia W, Zhou J, Luo H. et al. MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7. Cancer Cell Int 2017; 17: 14
    CrossrefPubMedSearch in Google Scholar